Palatin Technologies, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2016 (filed September 19, 2016). The filing is an annual report, not a report for calendar 2015 Q4. Palatin is a clinical-stage biopharmaceutical company with no products commercially available; its lead candidate is bremelanotide for hypoactive sexual desire disorder (HSDD).
Financial performance and position
- Revenue: $0 in FY2016, versus $12.95 million in FY2015, primarily license and milestone revenue from Gedeon Richter. That agreement was terminated in September 2015, and the rights reverted to Palatin.
- Loss: Net loss was $51.71 million, or $0.33 per share, versus $17.67 million, or $0.15 per share, in FY2015. Operating expenses were $49.25 million, including $43.07 million of R&D, up from $30.24 million and $24.56 million, respectively.
- Cash flow: Cash used in operating activities was $47.36 million, compared with $13.36 million in FY2015. Cash and cash equivalents were $8.00 million at year-end; available-for-sale investments were $1.38 million.
- Liquidity and going concern: Current assets were $10.81 million and current liabilities $13.99 million. The auditor expressed substantial doubt about the company’s ability to continue as a going concern. Management said year-end resources plus about $8.5 million net proceeds from an August 2016 offering were expected to fund planned operations through December 31, 2016.
- Debt: Notes payable were $19.68 million net of discount ($20.0 million principal); total liabilities were $28.64 million. FY2016 interest expense was $2.51 million. The venture loans bear interest at one-month LIBOR, subject to a 0.50% floor, plus 8.50%.
- Equity and dilution: Stockholders’ equity was negative $17.59 million, and accumulated deficit was $343.41 million. The August 2016 offering raised $9.23 million gross and included common shares and warrants.
Profit margins are not meaningful for this pre-commercial company, which reported no FY2016 revenue. No cash dividends are anticipated.
Material changes versus FY2015
- Revenue fell from $12.95 million to zero after the Gedeon Richter agreement ended.
- R&D expense rose 75% to $43.07 million, mainly due to the bremelanotide Phase 3 program. Operating cash use increased substantially, and net loss widened.
- Cash and cash equivalents declined from $27.30 million to $8.00 million, while net notes payable increased from $9.78 million to $19.68 million.
- Palatin completed a $20 million gross private placement in July 2015 and a $10 million venture loan; the later August 2016 offering provided additional near-term financing but also issued substantial shares and warrants.
Pipeline, outlook, and key risks
- Bremelanotide: The last visits in the double-blind efficacy portion of the two Phase 3 RECONNECT studies were completed in calendar Q3 2016. Topline results were projected for early Q4 2016; the open-label safety extension continued. The company anticipated an NDA submission in mid-2017, conditional on supportive results and additional studies, manufacturing work, and funding. Phase 3 efficacy and FDA approval were not assured.
- Other programs: PL-3994 was described as ready for Phase 2 studies in heart failure and other indications; initiation of a planned trial was contingent on adequate funds. PL-8177 and MC4r candidates remained in earlier development.
- Funding needs: Management estimated at least $87 million to complete the bremelanotide program, including regulatory filings; about $57 million had been expensed to date. Additional financing or collaboration is needed for the program and other candidates, and may be unavailable on acceptable terms.
- Commercial and execution risks: The company has no marketing partner for bremelanotide, depends on third parties for manufacturing and clinical work, and faces regulatory, safety, reimbursement, competition, and patent risks. Management expected limited third-party reimbursement for HSDD treatment.
- Other commitments: Contractual obligations totaled $27.38 million, including $23.89 million of notes payable and approximately $2.52 million in Catalent space-reservation fees. The company reported no current material legal proceedings.
Important facts for investors to verify
- Whether Phase 3 bremelanotide results supported efficacy and safety, and the subsequent regulatory and NDA timeline.
- Actual cash runway, financing requirements, and progress in securing a commercial partner or other funding.
- Debt repayment terms, interest burden, and the effect of outstanding warrants, preferred stock, and later financing on dilution.
- Manufacturing and device readiness, including supply arrangements, and the costs and obligations required before any NDA submission.
- Potential market access, pricing, and reimbursement for bremelanotide if approved.